Regulation of glutamate synthesis via inhibition of glutamate carboxypeptidase II (GCPII): An effective method to treat central and peripheral nervous system disorders

Current Medicinal Chemistry

Volumn 19, Issue 9, 2012, Pages 1259-1260

  Cavaletti, Guido ^a   Slusher, Barbara ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR 3; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; LAMOTRIGINE; METALLOPROTEINASE; N ACETYLASPARTYLGLUTAMIC ACID; RILUZOLE; TRANSFORMING GROWTH FACTOR BETA;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN FUNCTION; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM DISEASE; COGNITION; EDITORIAL; ENZYME INHIBITION; EPILEPSY; GENE ACTIVATION; GLIA CELL; LEARNING; MEMORY; MITOCHONDRION; NERVE CELL; NERVE CONDUCTION; NERVE ENDING; NEUROTRANSMISSION; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; ENZYME INHIBITORS; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMIC ACID; HUMANS; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84858118144     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799462577     Document Type: Editorial

References (12)

1. Low, S. J.; Roland, C. L., Review of NMDA antagonist-induced neurotoxicity and implications for clinical development. Int J Clin Pharmacol Ther 2004, 42 (1), 1-14. (Pubitemid 38100854)
2. Javitt, D. C.; Schoepp, D.; Kalivas, P. W.; Volkow, N. D.; Zarate, C.; Merchant, K.; Bear, M. F.; Umbricht, D.; Hajos, M.; Potter, W. Z.; Lee, C. M., Translating glutamate: from pathophysiology to treatment. Sci Transl Med 3 (102), 102mr2.
3. Gordon, P. H., Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management. CNS Drugs 25 (1), 1-15.
4. Syed, T. U.; Sajatovic, M., Extended-release lamotrigine in the treatment of patients with epilepsy. Expert Opin Pharmacother 11 (9), 1579-85.
5. Slusher, B. S.; Robinson, M. B.; Tsai, G.; Simmons, M. L.; Richards, S. S.; Coyle, J. T., Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. J Biol Chem 1990, 265 (34), 21297-301. (Pubitemid 120014152)
6. Wroblewska, B.; Wroblewski, J. T.; Pshenichkin, S.; Surin, A.; Sullivan, S. E.; Neale, J. H., N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 1997, 69 (1), 174-81. (Pubitemid 27274170)
7. Thomas, A. G.; Liu, W.; Olkowski, J. L.; Tang, Z.; Lin, Q.; Lu, X. C.; Slusher, B. S., Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-beta. Eur J Pharmacol 2001, 430 (1), 33-40. (Pubitemid 33042708)
8. Tsukamoto, T.; Wozniak, K. M.; Slusher, B. S., Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 2007, 12 (17-18), 767-76. (Pubitemid 47362787)
9. Zhou, J.; Neale, J. H.; Pomper, M. G.; Kozikowski, A. P., NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005, 4 (12), 1015-26.
10. Barinka, C.; Rojas, C.; Slusher, B.; Pomper, M., Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer. Curr Med Chem. 2012, Jan 2 [Epub ahead of publication]
11. Slusher, B. S.; Vornov, J. J.; Thomas, A. G.; Hurn, P. D.; Harukuni, I.; Bhardwaj, A.; Traystman, R. J.; Robinson, M. B.; Britton, P.; Lu, X. C.; Tortella, F. C.; Wozniak, K. M.; Yudkoff, M.; Potter, B. M.; Jackson, P. F., Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 1999, 5 (12), 1396-402.
12. van der Post, J. P.; de Visser, S. J.; de Kam, M. L.; Woelfler, M.; Hilt, D. C.; Vornov, J.; Burak, E. S.; Bortey, E.; Slusher, B. S.; Limsakun, T.; Cohen, A. F.; van Gerven, J. M., The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol 2005, 60 (2), 128-36.